Lisha Kallacheril
Endocrinology, Diabetes & Metabolism · Flemington, NJNPI 1346726296
Payments from drug & device makers
Across 294 payments — averaging $17.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$715
- Corcept Therapeutics$453
- Novo Nordisk$438
- Boehringer Ingelheim$323
- Bayer$300
- Radius Health, Inc.$249
- plus $3K from 34 others
What the payments were for
- Food & beverage$5,195100%
- Education$110%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 44 | $715 |
| Corcept Therapeutics | 28 | $453 |
| Novo Nordisk | 33 | $438 |
| Boehringer Ingelheim | 19 | $323 |
| Bayer | 15 | $300 |
| Radius Health, Inc. | 12 | $249 |
| Dexcom, Inc. | 10 | $217 |
| Tandem Diabetes Care, Inc. | 8 | $213 |
| Sanofi-aventis U.S. LLC | 11 | $192 |
| Mannkind Corporation | 12 | $192 |
| Amgen | 11 | $190 |
| Xeris Pharmaceuticals, Inc. | 12 | $183 |
| Insulet Corporation | 6 | $139 |
| Amneal Pharmaceuticals LLC | 8 | $135 |
| Antares Pharma, Inc. | 2 | $121 |
| Recordati_rare_diseases_inc. | 7 | $120 |
| AstraZeneca(2 entities) | 6 | $107 |
| Medtronic | 4 | $93 |
| Novartis | 5 | $87 |
| Tolmar, Inc. | 5 | $80 |
| Cequr Corporation | 3 | $76 |
| Abbott | 3 | $56 |
| Acella Pharmaceuticals, LLC | 3 | $55 |
| Intuity Medical Inc | 3 | $49 |
| IBSA Pharma Inc. | 3 | $49 |
| AbbVie | 3 | $45 |
| BETA Bionics, Inc. | 1 | $40 |
| Neurocrine Biosciences, Inc. | 2 | $36 |
| Soleno Therapeutics, Inc. | 2 | $34 |
| Embecta Corp. | 2 | $31 |
| Currax Pharmaceuticals LLC | 2 | $29 |
| Halozyme Inc | 1 | $22 |
| Madrigal Pharmaceuticals | 1 | $20 |
| Eisai Inc. | 1 | $20 |
| GSK | 1 | $17 |
| Sequel Med Tech, LLC | 1 | $17 |
| Kyowa Kirin, Inc. | 1 | $17 |
| Amphastar Pharmaceuticals, Inc. | 1 | $16 |
| Lifescan, Inc. | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $15 |
How this compares
$5,205 in reported general payments places this provider in the 70th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.
See all endocrinology, diabetes & metabolism providers in New Jersey →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 166 | $198,065 |
| MounjaroTirzepatide | 91 | $101,362 |
| TrulicityDulaglutide | 84 | $98,839 |
| JardianceEmpagliflozin | 92 | $88,101 |
| JanuviaSitagliptin Phosphate | 51 | $41,392 |
| Tresiba Flextouch U-200Insulin Degludec | 51 | $37,333 |
| FarxigaDapagliflozin Propanediol | 29 | $29,400 |
| RybelsusSemaglutide | 26 | $29,195 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 27 | $24,179 |
| Bydureon BciseExenatide Microspheres | 24 | $19,477 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 15 | $14,853 |
| Humalog Kwikpen U-200Insulin Lispro | 14 | $14,232 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 114 | $12,078 |
| TradjentaLinagliptin | 22 | $11,881 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 32 | $11,583 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $438 | $227,259192 claims |
| Lilly USA, LLCMounjaro, Trulicity | $715 | $200,201175 claims |
| Boehringer IngelheimJardiance, Tradjenta | $323 | $99,982114 claims |
| AstraZenecaFarxiga | $107 | $29,40029 claims |
| Amneal Pharmaceuticals LLCUnithroid, Levothyroxine Sodium | $135 | $1,73092 claims |
| AbbVieSynthroid | $45 | $1,51820 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.
Other endocrinology, diabetes & metabolism in Flemington
- Marc SandbergFlemington$567K
- Robert LindFlemington$32K
- Barry GertzRahway$903K
- Nawras MakhsidaRandolph$882K
- Joanne WaldstreicherNew Brunswick$441K
- Gregory BaroneCherry Hill$433K
- Taher ModarressiPennington$414K
- Navtika DesaiHillsborough$408K
- Atara SchultzTeaneck$357K
- Anthony CannonTurnersville$296K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.